A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Taspoglutide on Gastric Emptying Measured by a Paracetamol Test After Single Dose and After Multiple Doses in Patients With Type 2 Diabetes.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Taspoglutide on Gastric Emptying Measured by a Paracetamol Test After Single Dose and After Multiple Doses in Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Taspoglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics; Registrational
  • Acronyms T-EMERGE-6
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2011 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 17 Jun 2010 To reduce the risk of hypersensitivity reactions associated with taspoglutide, Roche has amended T-EMERGE trial protocols to include a risk management plan (involving monitoring of anti-drug antibody levels), according to an Ipsen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top